We are live on ! Find out more
CRBU icon

Caribou Biosciences

126 hedge funds and large institutions have $238M invested in Caribou Biosciences in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 33 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 33

1.93% more ownership

Funds ownership: 71.46%73.39% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

5% less funds holding

Funds holding: 133126 (-7)

12% less call options, than puts

Call options by funds: $99K | Put options by funds: $112K

13% less capital invested

Capital invested by funds: $273M → $238M (-$34.8M)

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

Holders
126
Holders Change
-7
Holders Change %
-5.26%
% of All Funds
2.01%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
49
Reduced
33
Closed
19
Calls
$99K
Puts
$112K
Net Calls
-$13K
Net Calls Change
-$540K
Name Holding Trade Value Shares
Change
Change in
Stake
PHS
1
PFM Health Sciences
California
$26.6M +$3.44M +552,335 +12%
BlackRock
2
BlackRock
New York
$25.2M +$202K +32,480 +0.7%
State Street
3
State Street
Massachusetts
$17.8M +$974K +156,399 +5%
APM
4
Avidity Partners Management
Texas
$14.6M -$772K -124,000 -4%
RCMU
5
Rokos Capital Management (UK)
United Kingdom
$14.1M
Bank of America
6
Bank of America
North Carolina
$14M +$4.91M +788,483 +43%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.8M +$161K +25,844 +1%
EWM
8
Elmwood Wealth Management
California
$12.6M
PAMS
9
Pictet Asset Management (Switzerland)
Switzerland
$11M -$3.04M -487,702 -19%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$7.67M +$4.84K +777 +0.1%
Morgan Stanley
11
Morgan Stanley
New York
$6.63M +$125K +20,081 +2%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$5.68M +$241K +38,637 +4%
Alkeon Capital Management
13
Alkeon Capital Management
New York
$5.6M -$24.7K -3,958 -0.4%
Fidelity International
14
Fidelity International
Bermuda
$4.57M
Assenagon Asset Management
15
Assenagon Asset Management
Luxembourg
$4.48M -$73K -11,713 -1%
MC
16
Maverick Capital
Texas
$3.46M
JP Morgan Chase
17
JP Morgan Chase
New York
$3.2M +$17.9K +2,881 +0.5%
TCM
18
Tekla Capital Management
Massachusetts
$3.01M
MSKCC
19
Memorial Sloan Kettering Cancer Center
New York
$2.89M
Northern Trust
20
Northern Trust
Illinois
$2.81M -$34.1K -5,482 -1%
7IH
21
72 Investment Holdings
Connecticut
$2.52M
IBT
22
International Biotechnology Trust
United Kingdom
$2.43M +$1.25M +200,000 +78%
Charles Schwab
23
Charles Schwab
California
$2.18M +$34.5K +5,547 +1%
Millennium Management
24
Millennium Management
New York
$1.73M +$529K +84,972 +35%
Goldman Sachs
25
Goldman Sachs
New York
$1.67M -$244K -39,128 -11%

CRBU Hedge Fund Activity: Q1 2023 in Review

126 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q1 2023, worth a combined $238M — down 13% from $273M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of CRBU and 13 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 49 added.

The largest buyer was Bank of America, adding an estimated $4.91M. The largest seller was Pictet Asset Management (Switzerland), cutting an estimated $3.04M.

  • 126 institutional investors held Caribou Biosciences (CRBU) as of Q1 2023, down from 133 in Q4 2022.
  • Funds reported $238M of Caribou Biosciences stock for Q1 2023, down 13% quarter-over-quarter.
  • 13 funds opened new Caribou Biosciences positions in Q1 2023 and 19 closed out, a net change of -6 holders.
  • The largest Caribou Biosciences buyer in Q1 2023 was Bank of America, an estimated $4.91M added.
  • The largest Caribou Biosciences seller in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $3.04M sold.

Based on aggregated 13F filings for Q1 2023.